Skip to main content
. 2021 Jul 16;9(7):831. doi: 10.3390/biomedicines9070831

Figure 4.

Figure 4

The effect of Tofacitinib Citrate on IL-17A-induced barrier dysfunction and claudin-5 junction dysmorphia in bEnd.3 cells. The bEnd.3 cells were pretreated with Tofacitinib Citrate (4.955 µM) for 30 min, followed by IL-17A (100 ng/mL) incubation for 30 min. TEER and claudin-5 expression in bEnd.3 cells was examined 72 h later. (A) Scheme of experimental design. (B) TEER in bEnd.3 cells from different groups. UT, untreated; Mean ± SD; *** p < 0.001, **** p ≤ 0.0001 by One-Way ANOVA with Tukey’s multiple comparisons test. (C) Immunostaining for claudin-5 (red), DAPI (blue). Scale bar = 25 µm.